Cohance Lifesciences Limited CC-May26.pdf · 2026-05-12
Hi team, now with Umang on board and some reshuffling and some rethinking will invariably happen. As shareholders, we look forward to some growth. Can I just clarify that when we say H2 from current fiscal of H2 we will revert back to growth, will we be measuring ourselves against the previous Y-o-Y basis or the FY25, which was the last growth Q3 and Q4 of fiscal 25? Are we benchmarking our growth or expecting that growth to come on the on that base, the higher base?
Sure, that is helpful. And if I could just conclude with my second question. I mean, what is likely to be the hardest decision for you as the team you will need to make at Cohance in the next 18 to 12 months? Because ours is a regulated business, it is a relationship-based business where trust compounds over many years with our customers. So in that context, what you think is the biggest priority for the team to sort of rebuild that confidence both with regulators and the customers so that when we get back to growth, we stay in growth mode for a very long period. Thank you.